Last reviewed 2026-04-20 · How we verify

NPI-2358

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Alopecia
• Bone pain
• Anemia
• Hyperglycemia
• Leukopenia
• Neutropenia
• Nausea
• Asthenia
• Neutrophil count decreased
• White blood cell count decreased
• Alanine aminotransferase increased
• Aspartate aminotransferase increased

Key clinical trials

• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies (PHASE1, PHASE2)
• Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) (PHASE3)
• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (PHASE1, PHASE2)
• Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) (PHASE2)
• Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) (PHASE1)
• Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) (PHASE2)
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC (PHASE2)
• Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3 (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.